Skip to main content
Erschienen in: World Journal of Urology 1/2024

01.12.2024 | Original Article

Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer

verfasst von: Hiranya Deka, Ginil Kumar Pooleri, Badiginchala Suguna, Ramiah Rajeshkannan, Resmi Sekhar, M. R. Bindhu, Vishnu Prasad

Erschienen in: World Journal of Urology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare diagnostic accuracy in localization and detection of extraprostatic extension (EPE), seminal vesicle invasion (SVI), lymph node involvement (LNI) between PSMA PET MRI and multiparametric MRI (mpMRI) in carcinoma prostate.

Methods

We did a prospective study of consecutive men with biopsy-proven prostate cancer who underwent radical prostatectomy between July’2020 and Dec’2021 at our institution. Patients underwent PSMA PET MRI imaging. MpMRI findings were inferred separately by another radiologist who was blinded to the PSMA PET findings. PIRADS > 2 and any standardized uptake value (SUV) were considered positive. Findings were mapped to a 30-region anatomical grid and compared with pathology. The uro-pathologist also marked the presence of the tumor onto the same anatomical grid. The presence of EPE, SVI, and LVI was noted. Outcome measurements and statistical analysis: The significance in difference: McNemar test. SUVmax and Gleason score: Kruskal–Wallis test.

Results

Seventy-five men (mean age 65) with an average PSA of 21.5 ng/ml were included. The sensitivity of PSMA PET MRI for localization was higher [63.6 vs 41.9] (p < 0.001) while specificity was similar [81.5 vs 83.2] (p 0.103). The former had a higher sensitivity to detect SVI [85.7 vs 57.10] (p = 0.03). No difference in the detection of EPE or LNI was noted. SUVmax > 7 was associated with high-risk disease (Gleason score >/= 7). Limitations: non-randomized nature, higher risk population.

Conclusion

Ga-PSMA PET MRI improved the localization of prostate cancer and better detection of SVI. Further studies are required. It can act as a single-stop investigation for the primary staging of prostate cancer.
Literatur
1.
Zurück zum Zitat Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249CrossRefPubMed
2.
Zurück zum Zitat Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S et al (2020) ICMR-NCDIR-NCRP Investigator Group. Cancer statistics, 2020: report from national cancer registry program, India. JCO Glob Oncol 6:1063–1075CrossRefPubMed Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S et al (2020) ICMR-NCDIR-NCRP Investigator Group. Cancer statistics, 2020: report from national cancer registry program, India. JCO Glob Oncol 6:1063–1075CrossRefPubMed
3.
Zurück zum Zitat Bratan F et al (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019CrossRefPubMed Bratan F et al (2013) Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol 23:2019CrossRefPubMed
4.
Zurück zum Zitat Johnson DC et al (2019) Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 75:712CrossRefPubMed Johnson DC et al (2019) Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol 75:712CrossRefPubMed
5.
Zurück zum Zitat Weinreb JC et al (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69:16CrossRefPubMed Weinreb JC et al (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69:16CrossRefPubMed
6.
Zurück zum Zitat Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD (1994) Expression of the prostate specific membrane antigen. Cancer Res 54(7):1807–1811PubMed Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD (1994) Expression of the prostate specific membrane antigen. Cancer Res 54(7):1807–1811PubMed
7.
Zurück zum Zitat Corfield J et al (2018) (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519CrossRefPubMed Corfield J et al (2018) (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 36:519CrossRefPubMed
8.
Zurück zum Zitat Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A (2022) Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol 5(1):1–7CrossRefPubMed Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A (2022) Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol 5(1):1–7CrossRefPubMed
9.
Zurück zum Zitat Chen M, Zhang Q, Zhang C, Zhou YH, Zhao X, Fu Y, Gao J, Zhang B, Wang F, Qiu X et al (2020) Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol 9:382–390CrossRefPubMedPubMedCentral Chen M, Zhang Q, Zhang C, Zhou YH, Zhao X, Fu Y, Gao J, Zhang B, Wang F, Qiu X et al (2020) Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer. Transl Androl Urol 9:382–390CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70(5):829–836CrossRefPubMed Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70(5):829–836CrossRefPubMed
11.
Zurück zum Zitat Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L (2018) Diagnostic accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology 289(3):730–737CrossRefPubMed Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L (2018) Diagnostic accuracy of 68Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology 289(3):730–737CrossRefPubMed
12.
Zurück zum Zitat Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS et al (2019) Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology 293(2):350–358CrossRefPubMed Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS et al (2019) Diagnostic accuracy of multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for extracapsular extension and seminal vesicle invasion in patients with prostate cancer. Radiology 293(2):350–358CrossRefPubMed
13.
Zurück zum Zitat Turkbey B, Pinto PA, Mani H et al (2010) Prostate cancer: the value of multiparametric MR imaging at 3 T for detection—histopathologic correlation. Radiology 255(1):89–99CrossRefPubMedPubMedCentral Turkbey B, Pinto PA, Mani H et al (2010) Prostate cancer: the value of multiparametric MR imaging at 3 T for detection—histopathologic correlation. Radiology 255(1):89–99CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Perera M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403CrossRefPubMed Perera M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403CrossRefPubMed
15.
Zurück zum Zitat Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H, Burger IA, Schöder H, Vargas HA (2020) Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging 4(1):1–15CrossRef Woo S, Ghafoor S, Becker AS, Han S, Wibmer AG, Hricak H, Burger IA, Schöder H, Vargas HA (2020) Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis. Eur J Hybrid Imaging 4(1):1–15CrossRef
Metadaten
Titel
Comparison of Ga-PSMA PET MRI with mpMRI in localization and regional staging of prostate cancer
verfasst von
Hiranya Deka
Ginil Kumar Pooleri
Badiginchala Suguna
Ramiah Rajeshkannan
Resmi Sekhar
M. R. Bindhu
Vishnu Prasad
Publikationsdatum
01.12.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2024
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-024-04873-x

Weitere Artikel der Ausgabe 1/2024

World Journal of Urology 1/2024 Zur Ausgabe

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.